IL-17 in type II diabetes mellitus (T2DM) immunopathogenesis and complications; molecular approaches.

Autor: Elahi R; School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran., Nazari M; School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran., Mohammadi V; School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran., Esmaeilzadeh K; Department of Medical Nanotechnology, Faculty of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran., Esmaeilzadeh A; Department of Immunology, Zanjan University of Medical Sciences, Zanjan, Iran; Cancer Gene Therapy Research Center (CGRC), Zanjan University of Medical Sciences, Zanjan, Iran. Electronic address: A46reza@zums.ac.ir.
Jazyk: angličtina
Zdroj: Molecular immunology [Mol Immunol] 2024 Jul; Vol. 171, pp. 66-76. Date of Electronic Publication: 2024 May 24.
DOI: 10.1016/j.molimm.2024.03.009
Abstrakt: Chronic inflammation has long been considered the characteristic feature of type II diabetes mellitus (T2DM) Immunopathogenesis. Pro-inflammatory cytokines are considered the central drivers of the inflammatory cascade leading to β-cell dysfunction and insulin resistance (IR), two major pathologic events contributing to T2DM. Analyzing the cytokine profile of T2DM patients has also introduced interleukin-17 (IL-17) as an upstream regulator of inflammation, regarding its role in inducing the nuclear factor-kappa B (NF-κB) pathway. In diabetic tissues, IL-17 induces the expression of inflammatory cytokines and chemokines. Hence, IL-17 can deteriorate insulin signaling and β-cell function by activating the JNK pathway and inducing infiltration of neutrophils into pancreatic islets, respectively. Additionally, higher levels of IL-17 expression in patients with diabetic complications compared to non-complicated individuals have also proposed a role for IL-17 in T2DM complications. Here, we highlight the role of IL-17 in the Immunopathogenesis of T2DM and corresponding pathways, recent advances in preclinical and clinical studies targeting IL-17 in T2DM, and corresponding challenges and possible solutions.
Competing Interests: Declaration of Competing Interest The authors declare that the research was conducted without commercial or financial relationships that could be considered a potential conflict of interest.
(Copyright © 2024. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: